



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:  C07K 14/81, 5/10		A1	(11) International Publication Number: <b>WO 98/49197</b>
			(43) International Publication Date: 5 November 1998 (05.11.98)
<p>(21) International Application Number: PCT/CZ98/00019</p> <p>(22) International Filing Date: 27 April 1998 (27.04.98)</p> <p>(30) Priority Data: PV 1315-97 30 April 1997 (30.04.97) CZ  <i>30.04.97/30 mož</i></p> <p>(71) Applicant (for all designated States except US): VÚFB, A.S. [CZ/CZ]; Kouřimská 17, 130 60 Praha 3 (CZ).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): <input checked="" type="checkbox"/> KASAFÍREK, Evžen [CZ/CZ]; Lomená 27, 162 00 Praha 6 (CZ). PIHERA, Pavel [CZ/CZ]; Limuzská 530/507, 108 00 Praha 10 (CZ). ŠTURC, Antonín [CZ/CZ]; Kolářova 648/7, 143 00 Praha 4 (CZ). ŠEBDO, Aleksi [CZ/CZ]; Dominova 2470, 155 00 Praha 5 (CZ).</p> <p>(74) Agent: GUTTMANN, Michal; Rott, Růžička &amp; Guttmann, P.O. Box 71, 142 00 Praha 4 (CZ).</p>			
<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published  <i>With international search report.  Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			

(54) Title: OLIGOPEPTIDIC INHIBITORS OF ELASTASES AND METHODS OF PREPARATION THEREOF

## (57) Abstract

The invention relates to oligopeptidic inhibitors of elastases, with potent inhibition of leukocyte elastase. The inhibitors are isobutylamides of tetra- to pentapeptides which have substituted lysine incorporated in the N-terminal portion of the molecule. This dibasic aminoacid is alternatively substituted at both  $\alpha$ - and  $\epsilon$ -aminogroups with higher saturated acids or with  $\omega$ -carboxylalkanoic residues. In one type of these compounds the  $\epsilon$ -aminogroup is acylated with an acyl-alanine, where an acyl means a higher saturated acid. The compounds of this invention are the active components of medicinal preparations used mainly in dental practice.